We are live on
!
Find out more
ACM
ADAR1 Capital Management Portfolio holdings
AUM
$1.66B
1-Year Est. Return
340.85%
This Fund
S&P 500
This Quarter
Est. Return
+8.25%
1 Year Est. Return
+340.85%
3 Year Est. Return
–
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$1.66B
AUM Growth
+$327M
(+24%)
Cap. Flow
+$308M
Cap. Flow
% of AUM
18.5%
Top 10 Holdings %
Top 10 Hldgs %
40.47%
Holding
329
New
71
Increased
98
Reduced
59
Closed
29
Top Buys
| 1 |
Beam Therapeutics
BEAM
|
+$40.1M |
| 2 |
Crinetics Pharmaceuticals
CRNX
|
+$37.1M |
| 3 |
Denali Therapeutics
DNLI
|
+$36.2M |
| 4 |
Inspire Medical Systems
INSP
|
+$27.3M |
| 5 |
Vir Biotechnology
VIR
|
+$21.9M |
Top Sells
| 1 |
RNAM
Avidity Biosciences
RNAM
|
+$39.4M |
| 2 |
RAPT
RAPT Therapeutics
RAPT
|
+$17.3M |
| 3 |
CDTX
Cidara Therapeutics
CDTX
|
+$13.2M |
| 4 |
Fulcrum Therapeutics
FULC
|
+$10.4M |
| 5 |
Arbutus Biopharma
ABUS
|
+$9.98M |
Sector Composition
| 1 | Healthcare | 90.27% |
| 2 | Financials | 1.54% |
| 3 | Technology | 0.08% |
| 4 | Industrials | 0.08% |
| 5 | Materials | 0.08% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
76
Protara Therapeutics
TARA
$226M
| $4.9M | 0.29% |
940,512
-196,287
| -17% | -$1.16M |
|
|
ABVX
77
CALL
Abivax
ABVX
$11.9B
| $4.9M | 0.29% |
+44,000
| New | +$5.21M |
|
78
Agios Pharmaceuticals
AGIO
$2.32B
| $4.76M | 0.29% |
140,672
-47,328
| -25% | -$1.34M |
|
79
Eli Lilly
LLY
$1.05T
| $4.65M | 0.28% |
+5,060
| New | +$5.13M |
|
80
Dianthus Therapeutics
DNTH
$5.31B
| $4.62M | 0.28% |
+55,000
| New | +$3.19M |
|
81
Arrowhead Research
ARWR
$10.3B
| $4.41M | 0.26% |
70,300
+12,100
| +21% | +$766K |
|
|
BLTE
82
Belite Bio
BLTE
$6.01B
| $4.29M | 0.26% |
26,880
-12,959
| -33% | -$2.18M |
|
|
EVMN
83
Evommune Inc
EVMN
$441M
| $4.23M | 0.25% |
184,062
| – | – |
|
84
Mineralys Therapeutics
MLYS
$2.4B
| $4.19M | 0.25% |
154,686
+18,455
| +14% | +$541K |
|
85
Janux Therapeutics
JANX
$978M
| $4.15M | 0.25% |
298,546
+53,094
| +22% | +$728K |
|
|
CLYM
86
Climb Bio
CLYM
$740M
| $4.09M | 0.25% |
597,662
-834,813
| -58% | -$4.82M |
|
87
Palisade Bio
PALI
$342M
| $3.96M | 0.24% |
2,264,845
+260,000
| +13% | +$473K |
|
|
AEXA
88
American Exceptionalism Acquisition Corp
AEXA
$590M
| $3.87M | 0.23% |
357,539
| – | – |
|
|
SPRB
89
Spruce Biosciences
SPRB
$124M
| $3.83M | 0.23% |
58,600
+600
| +1% | +$41.4K |
|
90
NewAmsterdam Pharma
NAMS
$3.75B
| $3.8M | 0.23% |
118,623
| – | – |
|
91
PUT
Liquidia Corp
LQDA
$6.92B
| $3.77M | 0.23% |
100,000
+75,500
| +308% | +$2.8M |
|
92
Zura Bio
ZURA
$492M
| $3.75M | 0.23% |
630,403
+68,338
| +12% | +$413K |
|
|
ACLX
93
DELISTED
Arcellx
ACLX
| $3.68M | 0.22% |
32,084
+600
| +2% | +$53K |
|
|
CTNM
94
Contineum Therapeutics
CTNM
$534M
| $3.61M | 0.22% |
276,661
-2,300
| -0.8% | -$30.9K |
|
95
Monte Rosa Therapeutics
GLUE
$1.96B
| $3.55M | 0.21% |
215,752
| – | – |
|
|
ONC
96
BeOne Medicines Ltd
ONC
$33.6B
| $3.47M | 0.21% |
+11,701
| New | +$3.79M |
|
97
Tenax Therapeutics
TENX
$401M
| $3.41M | 0.21% |
213,462
+149,789
| +235% | +$2.03M |
|
98
ArriVent BioPharma
AVBP
$1.49B
| $3.27M | 0.2% |
+141,814
| New | +$3.2M |
|
99
Pliant Therapeutics
PLRX
$68.7M
| $3.26M | 0.2% |
2,585,126
+2,511,307
| +3,402% | +$3.17M |
|
100
AtaiBeckley Inc
ATAI
$2.63B
| $3.23M | 0.19% |
913,242
| – | – |
|
Similar funds
GWM
GACM
RIA
CPO
NRI
JPM
GC
FA